Using a mystery caller approach to assess dimensions of access to prostate cancer care, we found slightly shorter wait times at radiation oncology practices compared to urology, albeit for different clinical scenarios (elevated PSA for urology and newly diagnosed prostate cancer for radiation oncology), and higher Medicaid acceptance at radiation oncology practices. The gene discussed is KLK3; the disease is prostate carcinoma.